Our study provides novel evidence that, in in vitro experimental models of CDD, the GSK-3β/HDAC6 dual inhibitor, C11 [29], is more effective at recovering neuronal survival than treatment with a single inhibitor that is selective for GSK-3β. The gene discussed is HDAC6; the disease is craniodiaphyseal dysplasia.